Combinations of cannabinoids and N-acylethanolamines
The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.
1. A method for preventing or treating pain in a human subject in need thereof, comprising
administering to the subject a pharmaceutical composition in a therapeutically-effective amount to prevent or treat the pain,
wherein the composition comprises at least one phyto-cannabinoid or a salt thereof, and at least one N-acylethanolamine or a salt thereof,
wherein the at least one phyto-cannabinoid or salt thereof and the at least one N-acylethanolamine or salt thereof are present in the composition in a molar ratio of about 1:0.2 to about 1:2000, and
wherein the at least one phyto-cannabinoid is tetrahydrocannabinol (THC) or a salt thereof.
2. The method of claim 1 , wherein the molar ratio between the at least one phyto-cannabinoid or salt thereof, and the at least one N-acylethanolamine or salt thereof is between about 1:0.2 to about 1:5.
3. The method of claim 1 , wherein the molar ratio between the at least one phyto-cannabinoid or salt thereof, and the at least one N-acylethanolamine or salt thereof is between about 1:0.5 to about 1:2.
4. The method of claim 1 , wherein the molar ratio between the at least one phyto-cannabinoid or salt thereof, and the at least one N-acylethanolamine or salt thereof is between about 1:15 to about 1:1800.
5. The method of claim 1 , wherein the molar ratio between the at least one phyto-cannabinoid or salt thereof, and the at least one N-acylethanolamine or salt thereof is between about 1:25 to about 1:450.
6. The method of claim 1 , wherein the molar ratio between the at least one phyto-cannabinoid or salt thereof, and the at least one N-acylethanolamine or salt thereof is between about 1:50 to about 1:100.
7. The method of claim 1 , wherein the pharmaceutical composition comprises about 200-1800 mg of N-acylethanolamine or salt thereof.
8. The method of claim 7 , wherein the pharmaceutical composition comprises about 250 mg, about 500 mg, about 750 mg, about 1000 mg or about 1500 mg of N-acylethanolamine or salt thereof.
9. The method of claim 1 , wherein the at least one N-acylethanolamine is N-palmitoylethanolamine (PEA), Me-palmitoylethanolamide (Me-PEA), palmitoylcyclohexamide, palmitoylbutylamide, palmitoylisopropylamide, oleoylethanolamine (OEA), palmitoylisopropylamide (PIA), a salt thereof, or any combination thereof.
10. The method of claim 9 , wherein the at least one N-acylethanolamine is PEA or a salt thereof.
11. The method of claim 1 , wherein the pharmaceutical composition comprises THC or a salt thereof, and PEA or a salt thereof.
12. The method of claim 1 , wherein the pharmaceutical composition comprises about 0.5-10 mg of THC or a salt thereof, and about 200-1800 mg of PEA or a salt thereof.
13. The method of claim 1 , wherein the pharmaceutical composition comprises about 2.5-10 mg of THC or a salt thereof and about 250-1000 mg of PEA or a salt thereof.
14. The method of claim 1 , wherein the pharmaceutical composition comprises about 2.5 mg, about 5 mg, about 7.5 mg or about 10 mg of THC or a salt thereof, and about 250 mg, about 500 mg, about 750 mg or about 1000 mg of PEA or a salt thereof.
15. The method of claim 1 , wherein the pharmaceutical composition is formulated for oral, oral mucosal, nasal, sublingual, inhalational, topical, rectal, vaginal, parenteral, intravenous, intramuscular, or subcutaneous administration.
16. The method of claim 1 , wherein the administration of the at least one phyto-cannabinoid and the N-acylethanolamine is repeated.
17. The method of claim 1 , wherein the pain is an acute pain, chronic pain, or neuropathic pain.